Ò©Ô´ÐÔÅÁ½ðÉ­×ÛºÏÕ÷,´ÓÕïÁƵ½Ô¤·À¶¼ÔÚÕâÀï

±±¾©Æ¤Ñ×Ò½Ôº¼ò½é http://m.39.net/baidianfeng/a_9052278.html

ÅÁ½ðÉ­×ÛºÏÕ÷²¢²»µÈÓÚÅÁ½ðÉ­²¡£¨PD£©¡£ÑϸñÀ´½²£¬ÅÁ½ðÉ­²¡Ó¦¸Ã½Ð×öÔ­·¢ÐÔÅÁ½ðÉ­²¡£¬ÎÞÃ÷È·²¡Òò¡£¶øÅÁ½ðÉ­×ÛºÏÕ÷ÊǼ̷¢ÐԵģ¬Í¨³£ÓÉÄÔÍâÉË¡¢Öж¾¡¢Ò©Îï¡¢ÄÔѪ¹Ü²¡¡¢Ö×Áö¡¢Ñ×Ö¢µÈÔ­ÒòÒýÆð£¬È­Íõ°¢ÀïÍËÒÛʱ±ã±»Õï¶ÏΪÅÁ½ðÉ­×ÛºÏÕ÷¡£Ò©ÎïÊÇÒýÆðÅÁ½ðÉ­×ÛºÏÕ÷µÄ²¡ÒòÖ®Ò»¡£´ÓÁÙ´²±íÏÖ¿´£¬Ò©Ô´ÐÔÅÁ½ðÉ­×ÛºÏÕ÷£¨DIP£©ºÍPDºÜÏàËÆ£¬·Ç³£ÈÝÒ×ÎóÕï¡£±¾ÎĽ«¶ÔDIPµÄÕï¶Ï¡¢¼ø±ðÕï¶Ï¡¢Ô¤·ÀºÍÖÎÁƽøÐвûÊö¡£

Ò½Âöͨ±àÒëÕûÀí£¬Î´¾­ÊÚȨÇëÎð×ªÔØ¡£

DIPµÄ¸ÅÊö

DIPÊÇPDµÄµÚ¶þ´ó²¡Òò£¬·¢²¡ÄêÁä´Ó10¸öÔµ½96Ëê²»µÈ£¬°ëÊý»¼ÕßµÄÄêÁäÔÚ60-79ËêÖ®¼ä¡£ÆäÁÙ´²±íÏÖ¶àÑù£¬DIPͨ³£±íÏÖΪ¶Ô³ÆÐÔÉÙ¶¯-ǿֱ×ÛºÏÕ÷£¨akinetic-rigidsyndrome£©£¬¾²Ö¹ÐÔÕð²üºÍ¶³½á²½Ì¬¡£»Ø¹Ë¼ÈÍù¹ØÓÚDIPµÄÑо¿£¬Ñо¿ÈËÔ±µÃ³öÁËÒÔϽáÂÛ£ºÒ©Îï¡¢ÐÔ±ð²îÒì¶¼»áÓ°Ï컼ÕßµÄÁÙ´²±íÏÖ£¬DIPµÄÕð²üÂʽÏPD¸ü¸ßµÈ¡£±ÈÈ翹ÒÖÓôÒ©¡¢ÍâÖܶà°Í°·Þ׿¹¼Á¡¢ÖÐÊà¶à°Í°·Þ׿¹¼ÁºÍµÚÒ»´ú¿¹×é°·Ò©Îïµ¼ÖµÄDIP»¼Õß×î³£·¢Éúǿֱ£¬¶ø¸ÆÍ¨µÀ×è¶Ï¼ÁÒýÆðµÄDIP×î³£·¢ÉúÕð²ü¡£

DIPÓëPDµÄ¼ø±ðÕï¶Ï

DIPÒ»Ö±ÊÇPDÕï¶Ï±ê×¼ÖеÄÅųýÏî¡£DIPµÄÌØÕ÷ºÍPDºÜÏàËÆ£¬µ«²¢·ÇÍêȫһÑù£¬Í¨³£»áµ¼ÖÂÎóÕï¡£DIP²¡Çé½øÕ¹¿ì£¬Í¬Ê±Ö¢×´Ò²±È½ÏÑÏÖØ£¬ÔçÆÚ¿ÉÄÜ¾Í»á´æÔÚÆ½ºâÕϰ­¡¢Ò×ˤµ¹¡¢ÍÂ×Ö²»ÇåµÈÖ¢×´¡£×îÖØÒªµÄÇø±ðÊÇ»¼ÕßÓÐÎÞ·ÔàçàºÀà¡¢¶¡õ£±½Àà¡¢ÀûÉáÆ½¡¢ï®¼Á¡¢¦Á-¼×»ù¶à°Í¡¢¼×ÑõÂÈÆÕ°·¡¢·ú¹ðÀûµÈÓÃÒ©Ê·¡£Ä¿Ç°£¬ÉÏÊöÒ©ÎïµÄÓ¦ÓÃÏ൱ÆÕ±é£¬Ó¦ÒýÆðÖØÊÓ¡£Òź¶µÄÊÇ£¬³ý´ËÖ®Í⣬ĿǰûÓÐ×ã¹»µÄ²¡ÀýÊý¾ÝÖ§³Ö¸ù¾Ý»¼ÕßµÄÔ˶¯ÌØÕ÷Çå³þÇø·ÖDIPºÍPD£¬¸¨Öú¼ø±ð¿É²Î¿¼±í1¡£

±í1DIPÓëPDµÄ¸¨Öú¼ø±ð

ÄÇô£¬¶ÔÓÚ³¤ÆÚ½ÓÊÜ¿¹¾«Éñ²¡Ò©ÎïÖÎÁƲ¢Öð½¥·¢Õ¹ÎªPDµÄ»¼Õߣ¬³£³£»á³öÏÖÕâÑùµÄÒÉÎÊ£ºÕâÊÇÕæµÄPD»¹ÊÇDIP£¿ÔÚÕâЩÇé¿öÏ£¬ÄÔDAT-SPECTÏÔÏñÓÈÆäÓÐЧ£¬ÒòΪ¾¡¹Ü¿¹¾«Éñ²¡Ò©Îï¶Ô´óÄÔ¶à°Í°·ÄÜϵͳÓÐÏÔÖøÓ°Ï죬µ«ÕâЩҩÎï¶ÔÄÔ²¿¶à°Í°·×ªÔËÌ壨DAT£©µÄÇ׺ÍÁ¦¿ÉºöÂÔ²»¼Æ£¬²»»á¸Ä±äDATµÄÃܶȣ¬Òò´ËÒ©Îï¶ÔDAT-SPECTµÄÓ°Ïì¿ÉºöÂÔ²»¼Æ¡£

DIPµÄÖÎÁƾ­Ñé

DIP»¼Õß¾ùÓÐÃ÷È·µÄÓÃÒ©Ê·£¬Æð²¡¼±¡¢½øÕ¹Ñ¸ËÙ¡£È·ÈÏDIPºó£¬ÐèÒªÁ˽⻼ÕßµÄÒ©Îï²»Á¼·´Ó¦Ê·£¬Ò©ÎïÒýÆðµÄÅÁ½ðÉ­×ÛºÏÕ÷Óë¼ÁÁ¿´óСÓйأ¬¸ö±ð»¼ÕßÔò¿ÉÄܶԴËÀàÒ©ÎïÓÐÒ׸ÐÐÔ£¬Ó¦ÅжÏÔðÈÎÒ©Îï²¢Á¢¼´Í£Óã¬ÓÃÆäËûÎÞDIP·çÏÕµÄÒ©Îï´úÌæ¡£Ê¹ÓÃÐÂҩʱ£¬Ó¦½÷É÷²¢ÑÏÃܹ۲졣Èç¹ûÅжÏÊǵ¥´¿DIP£¬¿É²»Óÿ¹PDÒ©Î»òÕßÊÔÓÃÒ»¶Îʱ¼äºó¿É³¢ÊÔÍ£Ò©¡£

¶àÊýDIPÊÇ¿ÉÄæµÄ£¬¾ø´ó²¿·Ö»¼ÕßÔÚÍ£Ö¹·þÓÃÒ©ÎïºóÊýÖÜÖÁ6¸öÔºóÅÁ½ðÉ­×ÛºÏÕ÷µÄÖ¢×´¼´¿ÉÃ÷ÏÔ¼õÇá»òÏûʧ£¬ÎÞÐè½øÐÐÒ©ÎïÖÎÁÆ¡£ÔÚÒ»ÏîÓйØDIPµÄÖÎÁÆÑо¿ÖУ¬²ÉÈ¡¶à°ÍË¿ëÂÖÎÁƺ󲿷ֻ¼ÕßµÄÖ¢×´µÃµ½»º½â£¬µ«ÊDz¿·Ö»¼Õß֢״δ¼û»º½â£¬ÖÎÁÆÐ§¹û²»¼Ñ¡£ÇÒ»¼ÕßÔÚ²ÉÓöà°ÍË¿ëÂÖÎÁÆÆÚ¼ä£¬³£³öÏÖÒÔ賦µÀ²»ÊÊΪÖ÷µÄ²»Á¼·´Ó¦¡£ËäȻδ·¢ÉúÒò²»ÄÜÄÍÊܲ»Á¼·´Ó¦¶øÍ£Ò©µÄ»¼Õߣ¬µ«¸ÃÑо¿ÏÔʾ¶ÔDIP»¼Õß½øÐÐÒ©ÎïÖÎÁÆÐ§¹ûÍùÍù²»¼Ñ¡£¶ÔÓÚ²»ÄÜÍ£Ò©µÄ»¼Õߣ¬ÔòÓ¦¼õÁ¿¡£

Æð³õ¿¼ÂÇDIP£¬ÈôÍ£ÓÃÔðÈÎÒ©Îïºó²»¿ÉÄæ£¬¿ÉÄÜÊÇÒ©ÎïÓÕ·¢Ìáǰ·¢²¡µÄPD£¨Õ¼10%-25%£©£¬Ð迹PDÒ©Îï²¢¼°Ê±µ÷ÕûÓÃÒ©¡£Ë¼¿¼PDµÄ²¡Òò·Ö²ã¼°SWEDD£¨scanswithoutevidenceofdopaminergicdeficit£¬É¨ÃèÎÞ¶à°Í°·ÄÜȱ·¦Ö¤¾Ý£©½âÊÍ¡£

DIPµÄÔ¤·À²ßÂÔ

DIPµÄÖÎÁƺͿØÖƽÏÀ§ÄÑ£¬Òò´ËÔ¤·ÀÆä·¢ÉúÏÔµÃÓÈÎªÖØÒª¡£Ô¤·À²ßÂÔÈçÏ£º

£¨1£©Ê¹Óÿ¹¾«Éñ²¡Ò©Îïͨ³£Í¬Ê±¸øÓ迹µ¨¼îÄÜÒ©ÎÈç°¢ÍÐÆ·¡¢±½º£Ë÷µÈ£¬¿ÉʹҩÎïÒýÆðµÄÅÁ½ðÉ­×ÛºÏÕ÷¼õÇá»ò²»·¢Éú¡£µ«Èô»¼Õß¶Ô¿¹µ¨¼îÄÜÒ©ÎïÎÞЧ£¬ÔòÐèÒª¼õÉÙ¿¹¾«Éñ²¡Ò©ÎïµÄ¼ÁÁ¿¡¢Í£Ò©»ò¸ÄÓÃÆäËüÒ©Îï¡£

£¨2£©Ê¹ÓøÆÍ¨µÀ×èÖͼÁ·ú¹ðÀûົò¹ðÀûີÈҩʱ£¬ÁƳ̲»Ò˹ý³¤£¬¼ÁÁ¿ÒËС£¬ÇÒ¼äЪÓÃÒ©¸üΪºÏÀí£¬ÓÃÒ©¹ý³ÌÖÐÓ¦ÃÜÇй۲죬һµ©³öÏÖÖ¢×´Ó¦¾¡ÔçÍ£Óá£

£¨3£©ÓÉ賦¶¯Á¦Ò©¼°¸ÆÍ¨µÀ×èÖͼÁ¶øÒýÆðµÄÔ˶¯»ò×ËÊÆÐÔÕð²ü£¬±ØÒªÊ±¿ÉÑ¡Óñ½º£Ë÷»º½âÕð²ü£¬µ«ÀÏÄêÈËʹÓÃÈÝÒ×ÒýÆðÄòäóÁô¡£

£¨4£©×óÐý¶à°Í¶ÔÒ©Ô´ÐÔÅÁ½ðÉ­×ÛºÏÕ÷µÄЧ¹û²»Ã÷ÏÔ£¬Òò´Ë²»ÒË×÷ΪԤ·ÀÐÔÓÃÒ©¡£

£¨5£©×¢ÒâÒ©ÎïµÄ³Ù·¢·´Ó¦¡£±ÜÃâ²»±ØÒªµÄÁªºÏÓÃÒ©£¬Á˽⻼Õß×ÔÓÃÒ©Çé¿ö£¬±ÜÃâÖØ¸´ÓÃÒ©¡£

С½á

DIP¿ÉÒÔÔÚÍ£Ò©¡¢¼õÉÙ¼ÁÁ¿»ò¸ü»»¸±×÷ÓøüСµÄÒ©ÎïºóµÃÒÔÄæ×ª¡£ÁÙ´²Ò½ÉúÓ¦½÷É÷Ñ¡ÔñÒ©Îï£¬×¢ÖØÉñ¾­ÏµÍ³µÄ±£»¤¡£Ö»ÒªÎÒÃdzä·ÖÈÏʶ¡¢Á˽âDIPÁÙ´²Ìص㣬²¢Ìá¸ß¾¯Ì裬¹æ·¶ÓÃÒ©£¬ÊµÏÖÔçÔ¤·À¡¢Ôç·¢ÏÖ¡¢ÔçÖÎÁƵġ°ÈýÔ硱·½Õ룬±ã¿É¸ÄÉÆ»¼ÕßÉú»îÖÊÁ¿£¬Ô¤·À²¢¼õÉÙDIP¡£

²Î¿¼ÎÄÏ×£º[1]EmmanuelleBondon-Guitton,etal.Drug-InducedParkinsonism:AReviewof17Years¡¯ExperienceinaRegionalPharmacovigilanceCenterinFrance[J].MovementDisorders,26£¨12£©,¨C.doi:10./mds..[2]MatthiasH€ollerhage.Secondaryparkinsonismduetodrugs,vascularlesions,tumors,trauma,andotherinsults[J].InternationalReviewofNeurobiology,Volume.doi:



×ªÔØÇë×¢Ã÷µØÖ·:http://www.jljizheng.com/ndwq/8999.html
  • ÉÏһƪÎÄÕ£º
  • ÏÂһƪÎÄÕ£º ûÓÐÁË
  • ÈȵãÎÄÕÂ

    • ûÓÐÈȵãÎÄÕÂ

    ÍÆ¼öÎÄÕÂ

    • ûÓÐÍÆ¼öÎÄÕÂ